Analysts Offer Predictions for Crinetics Pharmaceuticals, Inc.’s Q3 2025 Earnings (NASDAQ:CRNX)

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) – Equities researchers at Leerink Partnrs issued their Q3 2025 earnings estimates for shares of Crinetics Pharmaceuticals in a research note issued on Thursday, August 8th. Leerink Partnrs analyst J. Schwartz anticipates that the company will earn ($1.01) per share for the quarter. The consensus estimate for Crinetics Pharmaceuticals’ current full-year earnings is ($3.54) per share. Leerink Partnrs also issued estimates for Crinetics Pharmaceuticals’ Q4 2025 earnings at ($1.02) EPS.

A number of other research firms also recently commented on CRNX. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 target price on shares of Crinetics Pharmaceuticals in a research report on Tuesday, May 14th. Robert W. Baird boosted their price objective on shares of Crinetics Pharmaceuticals from $52.00 to $62.00 and gave the stock an “outperform” rating in a research note on Thursday, May 23rd. Oppenheimer reissued an “outperform” rating and set a $73.00 price target (down from $74.00) on shares of Crinetics Pharmaceuticals in a research report on Friday. HC Wainwright increased their target price on shares of Crinetics Pharmaceuticals from $60.00 to $69.00 and gave the company a “buy” rating in a research report on Friday. Finally, Morgan Stanley lifted their price target on shares of Crinetics Pharmaceuticals from $50.00 to $70.00 and gave the stock an “overweight” rating in a report on Thursday, May 23rd. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $64.75.

Crinetics Pharmaceuticals Trading Up 4.1 %

Shares of Crinetics Pharmaceuticals stock opened at $49.57 on Monday. The stock’s fifty day moving average price is $48.58 and its 200-day moving average price is $45.23. The firm has a market cap of $3.91 billion, a P/E ratio of -13.11 and a beta of 0.68. Crinetics Pharmaceuticals has a 12 month low of $15.76 and a 12 month high of $55.78.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.08). The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.47 million. The firm’s quarterly revenue was down 59.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.94) earnings per share.

Insider Activity at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, insider Stephen F. Betz sold 3,000 shares of Crinetics Pharmaceuticals stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $47.49, for a total transaction of $142,470.00. Following the completion of the sale, the insider now directly owns 86,643 shares in the company, valued at approximately $4,114,676.07. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Stephen F. Betz sold 3,000 shares of the stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $47.49, for a total value of $142,470.00. Following the sale, the insider now owns 86,643 shares in the company, valued at $4,114,676.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jeff E. Knight sold 27,000 shares of the company’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $55.00, for a total transaction of $1,485,000.00. Following the completion of the sale, the chief operating officer now directly owns 51,653 shares in the company, valued at $2,840,915. The disclosure for this sale can be found here. Insiders have sold a total of 170,016 shares of company stock worth $8,320,842 over the last quarter. Insiders own 6.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CRNX. Mirae Asset Global Investments Co. Ltd. boosted its position in Crinetics Pharmaceuticals by 6.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,218 shares of the company’s stock worth $1,395,000 after purchasing an additional 2,343 shares in the last quarter. abrdn plc acquired a new stake in Crinetics Pharmaceuticals during the fourth quarter valued at $3,601,000. Handelsbanken Fonder AB purchased a new position in Crinetics Pharmaceuticals in the fourth quarter valued at $445,000. Jennison Associates LLC raised its holdings in Crinetics Pharmaceuticals by 77.7% in the 4th quarter. Jennison Associates LLC now owns 2,547,683 shares of the company’s stock worth $90,647,000 after purchasing an additional 1,113,992 shares during the period. Finally, RWA Wealth Partners LLC acquired a new position in shares of Crinetics Pharmaceuticals during the 4th quarter worth approximately $203,000. 98.51% of the stock is currently owned by hedge funds and other institutional investors.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.